Navidea Biopharmaceuticals Incの収入

Navidea Biopharmaceuticals Incの収入 は何ですか。

Navidea Biopharmaceuticals Incの収入 は-6.88$です。

収入 の定義は何ですか。

普通株主に帰属する当期純利益は、純利益から優先配当金を差し引いた金額です。優先配当

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

NYSEMKTのセクタHealth Careにおける収入 の企業と比べるNavidea Biopharmaceuticals Inc

Navidea Biopharmaceuticals Incは何をしますか。

navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de

Navidea Biopharmaceuticals Incと類似の収入